Deeptech driven solutions for antibody development

MAbSilico and OSE immnotherapeutics sign a collaboration for the use of artifical intelligence in antibody development. OSE Immunotherapeutics plans to incorporate innovative problem-solving solutions like AI for the development of new monoclonal antibodies. MAbSilico solutions have already been tested and validated by OSE Immunotherapeutics and will be used for six antibody programs, including novel bispecific antibodies. AI and numerical simulation can guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the pre-clinical development process of these drug candidates before clinical tests.

https://mailchi.mp/9c82fbfe8704/mabsilico-signs-a-collaboration-with-ose-immunotherapeutics

MAbSilico has just been attributed a grant of one million euros in the Bpifrance I-Nov competition. This rewards its software, which uses artificial intelligence and numeric simulation to guide therapeutic antibody discovery, reducing the risk of failure and the time during the development of these drug candidates before clinical tests. A revolution in the bio-drugs development process.

https://mailchi.mp/d84d62a2f81e/mabsilico-awarded-for-a-1-m-grant-in-the-bpifrance-i-nov-competition?e=[UNIQID]

Join Us at the #7AIS2019 Congress @congress_ais – 24/25 June – Tours FR. #innovativeapproaches #therapeuticAbs #mAbs #immunotherapy

At the annual Proteins & Antibodies Congress, MAbSilico will present the in silico tools with our partner Synthelis for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators. Come to discuss about the most exciting breakthroughs for the discovery and development of antibodies..

Come to visit us during our presentation session.

This event in Lyon gather the French companies and organization using Artificial Intelligence for the developpment of immunotherapies..

Come to visit us at our booth.

Discover our tools MAbTope and how this AI-driven solution can accelerate and secure the intellectual property of you antibodies. Based on the Ab sequence, perform quick and reliable epitope mapping.

Read more about MAbTope.

At the European Antibody Congress, MAbSilico will present the in silico methods for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators to discuss the most exciting breakthroughs when it comes to the discovery and development of antibodies.

Come to visit us at the booth or during the poster session.

As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.

This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology.

The 6th Antibody Industrial Symposium 2018 (AIS2018) will be held the 25th and 26th of June 2018 in Montpellier, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).

Le Château is an accelerating program for early stage startups.

The second edition of the Immunotherapies for Infectious Diseases Congress - I4ID, that will be held in Lyon (France) on December 10-11, 2018, this year dedicated to Host-Directed Therapies (HDT) to fight infectious diseases.

The Hello Tomorrow Challenge is the world’s biggest early-stage startup competition for science and deep technology startups. Each year, they identify the best projects of the Challenge to attend the Hello Tomorrow Summit in Paris, an invite-only event bringing together the people that will change the world using science and technology around top investors in each sector, industrial leaders (Airbus, Google[x], Carrefour, Merck, Air Liquide, Facebook, etc.), international media (Bloomberg, BBC, Wired, etc.) and influencers (in 2016, Mike Bloomberg, Emmanuel Macron, CTO of Meta, CEO of Unity Biotech, etc).

Catalyzed by VIB’s Technology Scouting team, the Tools and Technologies meetings focus on the front end of innovation and bring together key innovators in selected life sciences research fields. The Next-Generation Antibodies and Protein Analysis conference, in Ghent (Belgium), is set to make another world class meeting, bringing together an exciting selection of top speakers and newly emerged companies. In addition to great scientific and technology program, the conference will provide ample networking opportunities.

We are happy to announce the incorporation of MAbSilico.